intact fgf 23 Search Results


mouse plasma fgf23  (Quidel)
95
Quidel mouse plasma fgf23
<t>FGF23</t> mRNA levels are increased in ALS muscle tissue. FGF23 mRNA levels were assessed in human muscle samples by qPCR using GAPDH as an internal housekeeping control. Disease samples were expressed as a fold-change (mean ± SEM) compared to normal control tissue (set at 1). *** P = 0.0001. BI, biceps brachii; DL, deltoid; GC, gastrocnemius; Myo, myopathy disease control; neuro, neuropathy disease control, TA, tibialis anterior; VL, vastus lateralis.
Mouse Plasma Fgf23, supplied by Quidel, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse plasma fgf23/product/Quidel
Average 95 stars, based on 1 article reviews
mouse plasma fgf23 - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier
fgf23  (Quidel)
95
Quidel fgf23
(A) Serum erythropoietin from sham WT (n = 7), nephrectomized WT (n = 5), nephrectomized WT+PBS (n = 8), sham BKO (n = 5), nephrectomized BKO (n = 4), and nephrectomized BKO+PBS mice (n = 3). (B) Serum <t>FGF23</t> from sham WT (n = 7), nephrectomized WT (n = 7), nephrectomized WT+PBS (n = 8), sham BKO (n = 5), nephrectomized BKO (n = 5), and nephrectomized BKO+PBS mice (n = 6). (C) Serum PTH from sham WT (n = 8), nephrectomized WT (n = 9), nephrectomized WT+PBS (n = 7), sham BKO (n = 6), nephrectomized BKO (n = 8), and nephrectomized BKO+PBS mice (n = 5). a p < 0.05 versus sham WT, b p < 0.05 versus nephrectomized WT, c p < 0.05 versus nephrectomized WT+PBS, d p < 0.05 versus sham BKO, and e p < 0.05 versus nephrectomized BKO.
Fgf23, supplied by Quidel, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fgf23/product/Quidel
Average 95 stars, based on 1 article reviews
fgf23 - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier

Image Search Results


FGF23 mRNA levels are increased in ALS muscle tissue. FGF23 mRNA levels were assessed in human muscle samples by qPCR using GAPDH as an internal housekeeping control. Disease samples were expressed as a fold-change (mean ± SEM) compared to normal control tissue (set at 1). *** P = 0.0001. BI, biceps brachii; DL, deltoid; GC, gastrocnemius; Myo, myopathy disease control; neuro, neuropathy disease control, TA, tibialis anterior; VL, vastus lateralis.

Journal: Scientific Reports

Article Title: FGF23, a novel muscle biomarker detected in the early stages of ALS

doi: 10.1038/s41598-021-91496-6

Figure Lengend Snippet: FGF23 mRNA levels are increased in ALS muscle tissue. FGF23 mRNA levels were assessed in human muscle samples by qPCR using GAPDH as an internal housekeeping control. Disease samples were expressed as a fold-change (mean ± SEM) compared to normal control tissue (set at 1). *** P = 0.0001. BI, biceps brachii; DL, deltoid; GC, gastrocnemius; Myo, myopathy disease control; neuro, neuropathy disease control, TA, tibialis anterior; VL, vastus lateralis.

Article Snippet: Human plasma FGF-23 was analyzed using U-PLEX Human FGF-23 Assay (K1516EK, MSD), and mouse plasma FGF23 was measure using mouse/rat FGF23 (intact) ELISA kit (60-6800, Quidel) according to the manufacturer’s instruction.

Techniques: Control

FGF23 protein is increased in ALS muscle tissue. Sections from 6 ALS and 4 normal muscle biopsy samples were immunostained with an anti-FGF23 antibody and counterstained with Hoechst and wheat germ agglutin (WGA). All 6 ALS patient samples but no control samples showed positive staining. Three of the ALS and two of the normal control sections are shown here. ALSp1 (deltoid), ALSp2 (vastus lateralis), ALSp3 (vastus lateralis), Ctrl1 (deltoid), Ctrl 2 (vastus lateralis). Asterisks highlight areas of grouped atrophy and arrowheads highlight several of the loci where FGF23 and WGA immunostaining colocalizes. Scale bars, 100 μm.

Journal: Scientific Reports

Article Title: FGF23, a novel muscle biomarker detected in the early stages of ALS

doi: 10.1038/s41598-021-91496-6

Figure Lengend Snippet: FGF23 protein is increased in ALS muscle tissue. Sections from 6 ALS and 4 normal muscle biopsy samples were immunostained with an anti-FGF23 antibody and counterstained with Hoechst and wheat germ agglutin (WGA). All 6 ALS patient samples but no control samples showed positive staining. Three of the ALS and two of the normal control sections are shown here. ALSp1 (deltoid), ALSp2 (vastus lateralis), ALSp3 (vastus lateralis), Ctrl1 (deltoid), Ctrl 2 (vastus lateralis). Asterisks highlight areas of grouped atrophy and arrowheads highlight several of the loci where FGF23 and WGA immunostaining colocalizes. Scale bars, 100 μm.

Article Snippet: Human plasma FGF-23 was analyzed using U-PLEX Human FGF-23 Assay (K1516EK, MSD), and mouse plasma FGF23 was measure using mouse/rat FGF23 (intact) ELISA kit (60-6800, Quidel) according to the manufacturer’s instruction.

Techniques: Control, Staining, Immunostaining

FGF23 immunoreactivity is higher in areas of grouped atrophy in human ALS muscle tissue. Using ImageJ Fluorescence Intensity (FI) Analysis function, we compared the FGF23 FI (per μM 2 ) of 37 atrophic fibers (< 25 μM minimal feret’s diameter) sampled from areas of grouped atrophy seen in 5 human ALS muscle samples with 37 non-atrophic fibers (> 25 μM minimal feret’s diameter) from the same sections. Representative photomicrographs of patient ALSp1 are shown with regions of interest highlighted for 6 grouped atrophic fibers (AF) and 6 non-atrophic fibers (NAF). An FGF23 intensity ratio was calculated by dividing the FI in atrophic fibers by the FI in non-atrophic factors for each patient. A ratio was also calculated between a similar number of non-atrophic fibers in the same section to the NAF region of interest as a control. The FI ratio was nearly sixfold higher in areas of grouped atrophy versus non-atrophic fibers. ** P = 0.006. Scale bar, 100 μm.

Journal: Scientific Reports

Article Title: FGF23, a novel muscle biomarker detected in the early stages of ALS

doi: 10.1038/s41598-021-91496-6

Figure Lengend Snippet: FGF23 immunoreactivity is higher in areas of grouped atrophy in human ALS muscle tissue. Using ImageJ Fluorescence Intensity (FI) Analysis function, we compared the FGF23 FI (per μM 2 ) of 37 atrophic fibers (< 25 μM minimal feret’s diameter) sampled from areas of grouped atrophy seen in 5 human ALS muscle samples with 37 non-atrophic fibers (> 25 μM minimal feret’s diameter) from the same sections. Representative photomicrographs of patient ALSp1 are shown with regions of interest highlighted for 6 grouped atrophic fibers (AF) and 6 non-atrophic fibers (NAF). An FGF23 intensity ratio was calculated by dividing the FI in atrophic fibers by the FI in non-atrophic factors for each patient. A ratio was also calculated between a similar number of non-atrophic fibers in the same section to the NAF region of interest as a control. The FI ratio was nearly sixfold higher in areas of grouped atrophy versus non-atrophic fibers. ** P = 0.006. Scale bar, 100 μm.

Article Snippet: Human plasma FGF-23 was analyzed using U-PLEX Human FGF-23 Assay (K1516EK, MSD), and mouse plasma FGF23 was measure using mouse/rat FGF23 (intact) ELISA kit (60-6800, Quidel) according to the manufacturer’s instruction.

Techniques: Fluorescence, Control

FGF23 is increased in SOD1 G93A muscle. ( A ) The clinical timeline of disease progression in the SOD1 G93A mouse is shown above . Below is a qPCR analysis of gastrocnemius muscle samples from littermate controls (WT) and SOD1 G93A mice at different ages as indicated. Data points are the mean ± SEM of 6–8 mice. * P < 0.05, *** P < 0.0005. ( B ) Photomicrographs of gastrocnemius muscle sections from a WT and SOD1 G93A mouse (60 d) immunostained with an anti-FGF23 antibody and counterstained with Hoechst and WGA. Scale bar, 100 μm. Arrowheads highlight several areas of merged FGF23 and WGA staining. ( C ) ELISA analysis of FGF23 in plasma samples obtained at the ages indicated. Data points are the mean ± SEM of 3 mice per group. ** P < 0.01.

Journal: Scientific Reports

Article Title: FGF23, a novel muscle biomarker detected in the early stages of ALS

doi: 10.1038/s41598-021-91496-6

Figure Lengend Snippet: FGF23 is increased in SOD1 G93A muscle. ( A ) The clinical timeline of disease progression in the SOD1 G93A mouse is shown above . Below is a qPCR analysis of gastrocnemius muscle samples from littermate controls (WT) and SOD1 G93A mice at different ages as indicated. Data points are the mean ± SEM of 6–8 mice. * P < 0.05, *** P < 0.0005. ( B ) Photomicrographs of gastrocnemius muscle sections from a WT and SOD1 G93A mouse (60 d) immunostained with an anti-FGF23 antibody and counterstained with Hoechst and WGA. Scale bar, 100 μm. Arrowheads highlight several areas of merged FGF23 and WGA staining. ( C ) ELISA analysis of FGF23 in plasma samples obtained at the ages indicated. Data points are the mean ± SEM of 3 mice per group. ** P < 0.01.

Article Snippet: Human plasma FGF-23 was analyzed using U-PLEX Human FGF-23 Assay (K1516EK, MSD), and mouse plasma FGF23 was measure using mouse/rat FGF23 (intact) ELISA kit (60-6800, Quidel) according to the manufacturer’s instruction.

Techniques: Biomarker Discovery, Staining, Enzyme-linked Immunosorbent Assay, Clinical Proteomics

Plasma FGF23 concentration.

Journal: Scientific Reports

Article Title: FGF23, a novel muscle biomarker detected in the early stages of ALS

doi: 10.1038/s41598-021-91496-6

Figure Lengend Snippet: Plasma FGF23 concentration.

Article Snippet: Human plasma FGF-23 was analyzed using U-PLEX Human FGF-23 Assay (K1516EK, MSD), and mouse plasma FGF23 was measure using mouse/rat FGF23 (intact) ELISA kit (60-6800, Quidel) according to the manufacturer’s instruction.

Techniques: Clinical Proteomics, Concentration Assay, Control

FGF23 in human plasma samples from ALS patients and healthy controls. ( A ) Baseline levels of log-transformed plasma FGF23 concentration (pg/ml) among controls, and faster and slower progressing ALS patients. Boxes show median (middle line), and 25th and 75th percentiles (lower and upper border, respectively); whiskers extend to a maximum of 1.5 × interquartile range (IQR), or to the most extreme value if it is less than 1.5 × IQR from the 25th or 75th percentile. ( B ) Longitudinal changes in log-transformed plasma FGF23 among controls. ( C ) Longitudinal changes in log-transformed plasma FGF23 among ALS slower progressors (ALSFRS-R decline < 0.8 point/month). ( D ) Longitudinal changes in log-transformed plasma FGF23 among ALS faster progressors (ALSFRS-R decline > 1.2 points/month).

Journal: Scientific Reports

Article Title: FGF23, a novel muscle biomarker detected in the early stages of ALS

doi: 10.1038/s41598-021-91496-6

Figure Lengend Snippet: FGF23 in human plasma samples from ALS patients and healthy controls. ( A ) Baseline levels of log-transformed plasma FGF23 concentration (pg/ml) among controls, and faster and slower progressing ALS patients. Boxes show median (middle line), and 25th and 75th percentiles (lower and upper border, respectively); whiskers extend to a maximum of 1.5 × interquartile range (IQR), or to the most extreme value if it is less than 1.5 × IQR from the 25th or 75th percentile. ( B ) Longitudinal changes in log-transformed plasma FGF23 among controls. ( C ) Longitudinal changes in log-transformed plasma FGF23 among ALS slower progressors (ALSFRS-R decline < 0.8 point/month). ( D ) Longitudinal changes in log-transformed plasma FGF23 among ALS faster progressors (ALSFRS-R decline > 1.2 points/month).

Article Snippet: Human plasma FGF-23 was analyzed using U-PLEX Human FGF-23 Assay (K1516EK, MSD), and mouse plasma FGF23 was measure using mouse/rat FGF23 (intact) ELISA kit (60-6800, Quidel) according to the manufacturer’s instruction.

Techniques: Clinical Proteomics, Transformation Assay, Concentration Assay

(A) Serum erythropoietin from sham WT (n = 7), nephrectomized WT (n = 5), nephrectomized WT+PBS (n = 8), sham BKO (n = 5), nephrectomized BKO (n = 4), and nephrectomized BKO+PBS mice (n = 3). (B) Serum FGF23 from sham WT (n = 7), nephrectomized WT (n = 7), nephrectomized WT+PBS (n = 8), sham BKO (n = 5), nephrectomized BKO (n = 5), and nephrectomized BKO+PBS mice (n = 6). (C) Serum PTH from sham WT (n = 8), nephrectomized WT (n = 9), nephrectomized WT+PBS (n = 7), sham BKO (n = 6), nephrectomized BKO (n = 8), and nephrectomized BKO+PBS mice (n = 5). a p < 0.05 versus sham WT, b p < 0.05 versus nephrectomized WT, c p < 0.05 versus nephrectomized WT+PBS, d p < 0.05 versus sham BKO, and e p < 0.05 versus nephrectomized BKO.

Journal: PLoS ONE

Article Title: High phosphate intake induces bone loss in nephrectomized thalassemic mice

doi: 10.1371/journal.pone.0268732

Figure Lengend Snippet: (A) Serum erythropoietin from sham WT (n = 7), nephrectomized WT (n = 5), nephrectomized WT+PBS (n = 8), sham BKO (n = 5), nephrectomized BKO (n = 4), and nephrectomized BKO+PBS mice (n = 3). (B) Serum FGF23 from sham WT (n = 7), nephrectomized WT (n = 7), nephrectomized WT+PBS (n = 8), sham BKO (n = 5), nephrectomized BKO (n = 5), and nephrectomized BKO+PBS mice (n = 6). (C) Serum PTH from sham WT (n = 8), nephrectomized WT (n = 9), nephrectomized WT+PBS (n = 7), sham BKO (n = 6), nephrectomized BKO (n = 8), and nephrectomized BKO+PBS mice (n = 5). a p < 0.05 versus sham WT, b p < 0.05 versus nephrectomized WT, c p < 0.05 versus nephrectomized WT+PBS, d p < 0.05 versus sham BKO, and e p < 0.05 versus nephrectomized BKO.

Article Snippet: Serum biochemistries were measured using ELISA kits for erythropoietin (R&D systems, Minneapolis, MN), FGF23 (Quidel, San Diego, CA), and PTH levels (Quidel, San Diego, CA).

Techniques: